Logo image
Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes
Journal article   Open access   Peer reviewed

Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes

Ming Ann Sim, Saima Hilal, Jasper Tromp, Eugene S J Tan, James Doecke, Oi Wah Liew, Vera Yuan Cai, Siew Pang Chan, Eddie Jun Yi Chong, Anqi Toh, …
Alzheimer's & dementia, Vol.22(8), e71728
08/2026
Handle:
https://hdl.handle.net/10523/52246

Abstract

Southeast‐Asian blood biomarker cerebrovascular disease cognition heart‐brain mortality proteomics
Introduction: The plasma proteomic signatures underlying cerebrovascular disease (CeVD) remains poorly understood. Methods: A total of N = 2534 participants across two independent longitudinal Southeast-Asian cohorts were included. We profiled 1441 baseline plasma proteins in a memory-clinic cohort (N = 518), followed-up for 4 years. Proteins associating with baseline and longitudinal CeVD lesions (i.e., white matter hyperintensity volume, lacunes, cerebral microbleeds, and cortical infarcts) were reported. The prognostic value of CeVD-associated proteins was evaluated for incident major cardiovascular/cerebrovascular events (MACCE) and mortality. External validation of key proteins for mortality was performed in the plasma proteome of an independent cardiovascular cohort (N = 2016). Results: We report distinct and overlapping plasma proteins for baseline and longitudinal CeVD, representing diverse biological processes. Four proteins were prioritized as mediators of CeVD-associated cognitive decline, and predictors of MACCE. These proteins were validated for incident mortality across both cohorts: neurofilament light chain (NEFL), latent-transforming growth factor beta-binding protein 2 (LTBP2), cysteine-rich motor neuron 1 protein (CRIM1), and urokinase plasminogen activator surface receptor (PLAUR). Discussion: The prognostic proteins prioritized in our study provide robust signals in two cohorts, representing potential mechanistic targets for CeVD and health outcomes.
pdf
Alzheimer s Dementia - 2026 - Sim - Plasma proteomics of cerebrovascular disease cognitive decline and clinical2.99 MBDownloadView
Published (Version of record) Open Access CC BY-NC-ND V4.0
url
https://doi.org/10.1002/alz.71728View
Published (Version of record) Open CC BY-NC-ND V4.0

Metrics

1 Record Views

Details

Logo image